REALIPINIVO: Clinical Activity of Nivolumab and Ipilimumab in Metastatic Melanoma

A real-world study from six academic centers in southern Italy analyzed efficacy and toxicity outcomes for 72 metastatic melanoma patients treated with nivolumab and ipilimumab. The dataset includes a 54% response rate and median progression-free survival of 17.03 months, with analysis of factors like tumor mutational burden and disease burden. Francesco Caraglia authored this study, last updated on 2026-04-16.

Use Cases

• Compare real-world progression-free survival to clinical trial benchmarks based on the reported 17.03-month median.
• Model predictors of treatment response based on features like tumor mutational burden and number of metastatic sites mentioned in the description.
• Analyze rates and management of immune-related adverse events compared to literature, based on the study's findings.
• Investigate survival correlations with objective response and low disease burden, as indicated by the provided p-values.

Strengths

• Includes data for 72 patients from a real-world clinical setting.
• Reports specific clinical metrics: 54% response rate and 17.03 months median progression-free survival.
• Analyzes correlations with concrete factors like tumor mutational burden and disease burden (<3 metastatic sites).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is limited to a 176.9 KB file, suggesting a small, focused scope.

Provenance

Source

figshare

Collection Method

Real-world study conducted across six academic centers.

Time Range

Study period not specified; dataset updated 2026-04-16.

Freshness

Last updated 2026-04-16 05:24:42; freshness should be verified.

Geography

Southern Italy.